Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Baclofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 known ✓ | O75899 | 8/20 | 1.00 |
| ▸ | GABBR1 known ✓ | Q9UBS5 | 8/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Baclofen SCHEMBL19333 | 1.00 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Arbaclofen SCHEMBL351220 | 1.00 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL19334 | 1.00 | GABBR2 (1.00) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Arbaclofen SCHEMBL1417519 | 0.98 | GABBR2 (0.96) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL656539 | 0.98 | GABBR2 (0.96) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL4915007 | 0.98 | GABBR2 (0.96) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL20815463 | 0.96 | GABBR2 (0.93) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Arbaclofen SCHEMBL2996117 | 0.96 | GABBR2 (0.93) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL3004536 | 0.96 | GABBR2 (0.93) | GABBR2GABBR1LMNACYP2C9CYP1A2 | |
| Baclofen SCHEMBL22352888 | 0.93 | GABBR2 (0.87) | GABBR2GABBR1LMNACYP2C9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11717483-B2 | Controlled release dosage form with enhanced pharmacokinetics | OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT (HU) | 2023-08-08 | — | — | US | disclosed |
| US-11679088-B2 | Controlled release dosage form | OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT (HU) | 2023-06-20 | — | — | US | disclosed |
| US-20210401785-A1 | Controlled Release Dosage Form | OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT (HU) | 2021-12-30 | — | — | US | disclosed |
| US-20210283062-A1 | Controlled Release Dosage Form with Enhanced Pharmacokinetics | OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT (HU) | 2021-09-16 | — | — | US | disclosed |
| US-11090281-B2 | Controlled release dosage form | OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT (HU) | 2021-08-17 | — | — | US | disclosed |
| US-10987328-B2 | Controlled release dosage form | OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT (HU) | 2021-04-27 | — | — | US | disclosed |
| US-10987312-B2 | Controlled release dosage form with enhanced pharmacokinetics | OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT (HU) | 2021-04-27 | — | — | US | disclosed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| US-20200188341-A1 | Controlled Release Dosage Form | OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT (HU) | 2020-06-18 | — | — | US | disclosed |
| US-20200129439-A1 | Controlled Release Dosage Form with Enhanced Pharmacokinetics | OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT (HU) | 2020-04-30 | — | — | US | disclosed |
| WO-2005063297-A2 | MELATONIN COMBINATION THERAPY FOR IMPROVING SLEEP QUALITY | SEPRACOR INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005063248-A1 | MODAFINIL COMBINATION THERAPY FOR IMPROVING SLEEP QUALITY | SEPRACOR INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005060968-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | SEPRACOR INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005037215-A2 | COMPOSITIONS AND METHODS FOR ENHANCING COGNITIVE FUNCTION AND SYNAPTIC PLASTICITY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005032556-A1 | METHOD FOR REDUCING PAIN | ELAN PHARMACEUTICALS, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| US-5149713-A | 4-amino-3-(4-chlorophenyl)-butyric acid | ADIR ET COMPAGNIE | 1992-09-22 | — | — | US | disclosed |
| US-4138484-A | CHLORPROMAZINE OR THORIDAZINE WITH G-HYDROXYBUTYROLACTONE | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1979-02-06 | — | — | US | disclosed |
| US-4129652-A | CHLORPROMAZINE OR THIORIDAZINE AND 5-ETHYL-5-PHENYL-2-PYRROLIDONE OR 1-HYDROXY-3-AMINO-2-PYRROLIDONE OR SALTS | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1978-12-12 | — | — | US | disclosed |
| US-4084000-A | NEUROLEPTIC, GAMMA-AMINOBUTYRIC ACID DERIVATIVES | NELSON RESEARCH AND DEVELOPMENT COMPANY (US) | 1978-04-11 | — | — | US | disclosed |
| US-3978216-A | AMINOOXYACETIC ACID | NELSON RESEARCH & DEVELOPMENT COMPANY (US) | 1976-08-31 | — | — | US | disclosed |